For example, in the case of ER+ tumor estrogen-receptor modulators, such as tamoxifen and letrozole are administered4, trastuzumab (Herceptin) is a humanized monoclonal antibody developed to target and inhibit the function of HER2 and a dual anti-HER2 regimen, pertuzumab in combination with trastuzumab and docetaxel are administered, however, the incidences of adverse events and resistance to these drugs are not uncommon5. Here, ERBB2 is linked to neoplasm.